IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.845
EU - Europa 1.594
AS - Asia 1.585
AF - Africa 246
SA - Sud America 180
OC - Oceania 5
Totale 5.455
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.778
SG - Singapore 701
IT - Italia 652
RU - Federazione Russa 627
CN - Cina 478
CI - Costa d'Avorio 147
BR - Brasile 146
KR - Corea 134
VN - Vietnam 98
IE - Irlanda 54
BD - Bangladesh 52
FR - Francia 52
GB - Regno Unito 38
FI - Finlandia 35
IN - India 35
CA - Canada 33
NG - Nigeria 27
DE - Germania 22
HK - Hong Kong 22
BJ - Benin 21
SN - Senegal 21
MX - Messico 20
PL - Polonia 17
NL - Olanda 16
SE - Svezia 16
AR - Argentina 15
UA - Ucraina 14
IQ - Iraq 13
ZA - Sudafrica 13
ES - Italia 11
JP - Giappone 10
TR - Turchia 10
BE - Belgio 9
CZ - Repubblica Ceca 7
VE - Venezuela 6
AU - Australia 5
EG - Egitto 5
PK - Pakistan 5
GT - Guatemala 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
CO - Colombia 3
DZ - Algeria 3
EC - Ecuador 3
HR - Croazia 3
LB - Libano 3
RO - Romania 3
AZ - Azerbaigian 2
CY - Cipro 2
JM - Giamaica 2
KZ - Kazakistan 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
PY - Paraguay 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
BF - Burkina Faso 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
HU - Ungheria 1
ID - Indonesia 1
KW - Kuwait 1
KY - Cayman, isole 1
LV - Lettonia 1
MA - Marocco 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SO - Somalia 1
SV - El Salvador 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 5.455
Salva come PNG Salva come JPEG
Città #
Singapore 478
Dallas 347
Moscow 330
Santa Clara 244
Hefei 237
San Jose 174
Ashburn 160
Abidjan 147
Seoul 133
Chicago 118
Catania 109
Los Angeles 87
Beijing 55
Dublin 52
Civitanova Marche 48
Palermo 46
Chandler 43
Milan 41
Rome 41
Boardman 38
Lauterbourg 38
Council Bluffs 36
Ho Chi Minh City 34
Buffalo 33
New York 33
Cotonou 21
Dakar 21
Hong Kong 19
São Paulo 19
Hanoi 18
Lagos 18
Lappeenranta 18
Orem 18
Warsaw 17
Montreal 16
Bari 13
Chennai 13
Florence 12
Helsinki 12
Johannesburg 12
San Giovanni la Punta 12
Stockholm 12
Amsterdam 11
Boston 11
Naples 11
Denver 10
Tokyo 10
Abuja 9
Brussels 9
London 9
Misterbianco 9
Paris 9
Phoenix 9
Rio de Janeiro 9
Turin 9
Bronte 8
Messina 8
Munich 8
San Francisco 8
Atlanta 7
Manchester 7
Mexico City 7
Poplar 7
Seattle 7
Washington 7
Belo Horizonte 6
Cambridge 6
Frankfurt am Main 6
Lawrence 6
Mumbai 6
Cassano delle Murge 5
Charlotte 5
City of London 5
Houston 5
Piazzola Sul Brenta 5
Turku 5
Acireale 4
Ankara 4
Baghdad 4
Brno 4
Brooklyn 4
Genoa 4
Haiphong 4
Kyiv 4
Melbourne 4
Piscataway 4
Pittsburgh 4
Aci Sant'Antonio 3
Amman 3
Bắc Ninh 3
Cairo 3
Caltagirone 3
Campinas 3
Can Tho 3
Curitiba 3
Lamezia Terme 3
Madrid 3
Manassas 3
Marseille 3
Militello in Val di Catania 3
Totale 3.715
Salva come PNG Salva come JPEG
Nome #
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 203
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 181
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 167
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 164
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 164
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 162
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 158
A case of high-risk AML in a patient with advanced systemic mastocytosis 157
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 156
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 144
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 140
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 137
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 136
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 131
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 129
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 127
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 126
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 126
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 125
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 125
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 123
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 121
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 121
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 120
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 118
Emergencies in Hematology: Why, When and How I Treat? 116
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 115
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 114
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 111
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 109
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 108
Chemotherapy extravasation: diagnosis, prevention and management 108
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 106
VEXAS-like syndrome: a potential new entity? 100
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 97
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 97
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study 92
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 91
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 90
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 82
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms 78
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 76
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 72
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 68
Myelofibrosis: In Search for BETter Targeted Therapies 59
Exploring the ABO haplotype and splanchnic thrombosis in patients with Primary Myelofibrosis 27
Pericytes and mesenchymal stromal cells converge toward pro-tumor phenotypes in the tumor microenvironment 16
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib 8
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model 7
Totale 5.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.842
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024474 26 60 22 55 13 88 33 36 6 17 80 38
2024/20251.189 16 174 41 114 190 121 60 45 71 85 123 149
2025/20263.521 226 425 411 224 425 765 263 83 233 228 156 82
2026/202742 42 0 0 0 0 0 0 0 0 0 0 0
Totale 5.508